Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
4 clinical trials · Condition
◉ Watch Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
| Record | Firm | Date |
|---|---|---|
| A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (NCT06901531) | Astellas Pharma Global Development, Inc. | 2025-05-22 |
| A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer. (NCT06902545) | Astellas Pharma Korea, Inc. | 2025-04-03 |
| A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). (NCT03653507) | Astellas Pharma Global Development, Inc. | 2018-11-28 |
| A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer. (NCT03504397) | Astellas Pharma Global Development, Inc. | 2018-06-21 |
Track Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer automatically
Every clearance here is in the API, with alerts when new ones post.